Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.2
4.8
Journals
Biomolecules
Special Issues
Molecular Profiling and Identification of Molecular Signatures Associated with Natural...
share announcement

Molecular Profiling and Identification of Molecular Signatures Associated with Natural Products: 2nd Edition

A special issue of Biomolecules (ISSN 2218-273X).

Deadline for manuscript submissions: 31 December 2025 | Viewed by 612

Special Issue Editor

Prof. Dr. Juei-Tang Cheng

E-Mail Website
Guest Editor
Department of Medical Research, Chi-Mei Medical Center, Tainan City 71004, Taiwan
Interests: natural products; pharmacology; diabetes; bioactivities; metabolic disorders; insulin resistance
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue is the second edition of a previous Special Issue entitled “Molecular Profiling and Identification of Molecular Signatures Associated with Natural Products” (https://www.mdpi.com/journal/biomolecules/special_issues/50A35GSFKO). Following a very successful first edition, we are pleased to announce the launch of the 2nd edition of this Special Issue.

Natural products (NPs) are a useful tool in the treatment of health-related conditions around the world, and they have been widely investigated for use on humans and animals. Because NPs have been applied for a significant period of time, they have been linked to functional disorders and the progression of diseases; many scientists have contributed to NP research. Their fruitful results have been beneficial to health and basic research. However, numerous areas have not been studied, particularly their molecular mechanisms. Therefore, this Special Issue aims to present a collection of articles focused on the in vivo and in vitro molecular mechanisms and effects of NPs. Recently, important molecules and/or signaling events in NPs have been discovered. The repurposing of NP is a popular topic. It is important to assess the significance of these molecules in the mechanisms of NPs. We encourage you to share NP findings that have been obtained in your lab using reliable animal models and/or the established cell models. Moreover, considering the health merits of modern therapies, this Special Issue will cover a wide variety of areas, including the repurposing of well-known molecules, with the aim of developing useful agents and/or biomolecules from NPs for clinical therapy. Reviews, mini-reviews, commentaries, and original research articles, among others, are welcome, and we look forward to receiving contributions from all over the world.

Prof. Dr. Juei-Tang Cheng
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • natural product
  • molecular mechanisms
  • repurposed molecules
  • disease model
  • human health

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

14 pages, 3486 KB  
Article
Asiatic Acid from Centella asiatica as a Potent EGFR Tyrosine Kinase Inhibitor with Anticancer Activity in NSCLC Cells Harboring Wild-Type and T790M-Mutated EGFR
by Chaiwat Monmai, Sahachai Sabuakham, Wachirachai Pabuprapap, Waraluck Chaichompoo, Apichart Suksamrarn and Panupong Mahalapbutr
Biomolecules 2025, 15(10), 1410; https://doi.org/10.3390/biom15101410 - 3 Oct 2025
Viewed by 414
Abstract
Lung cancer is a leading cause of cancer mortality worldwide. Targeted therapies with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) represent a significant advance in the management of lung cancer. However, their long-term efficacy is often limited by acquired resistance, particularly [...] Read more.
Lung cancer is a leading cause of cancer mortality worldwide. Targeted therapies with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) represent a significant advance in the management of lung cancer. However, their long-term efficacy is often limited by acquired resistance, particularly due to the T790M mutation, highlighting the need for novel EGFR-TKIs. Although compounds derived from Centella asiatica have demonstrated anticancer potential, their role in EGFR inhibition has not yet been reported. In this study, we investigated the inhibitory activity of two primary constituents, asiaticoside and asiatic acid, against wild-type and double-mutant (L858R/T790M) EGFR, as well as the anticancer effects of the more potent compound in lung cancer cells. A kinase activity assay revealed that asiatic acid potently inhibited both wild-type and double-mutant EGFR, whereas asiaticoside showed minimal inhibitory activity. Molecular docking demonstrated that asiatic acid bound to the ATP-binding pocket of both EGFR forms with binding energies superior to those of erlotinib and osimertinib. Treatment with asiatic acid significantly (i) reduced viability of A549 and H1975 cells while remaining non-toxic to BEAS-2B normal lung cells, (ii) enhanced cancer cell apoptosis, (iii) suppressed extracellular signal-regulated kinase (ERK) and protein kinase B (Akt) signaling pathways, and (iv) inhibited EGFR activation in A549 and H1975 cells. These results suggest that asiatic acid is a promising lead compound for anticancer drug development. Full article
(This article belongs to the Special Issue Molecular Profiling and Identification of Molecular Signatures Associated with Natural Products: 2nd Edition)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop